Research programme: Alzheimer's disease diagnostic agents - Bristol-Myers Squibb/Meso Scale Discovery
Latest Information Update: 12 Nov 2013
At a glance
- Originator Bristol-Myers Squibb
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 07 Nov 2013 Discontinued for Alzheimer's disease (diagnosis) in USA (unspecified route)
- 30 Mar 2012 Early research in Alzheimer's disease (diagnosis) in USA (unspecified route)